Curevo Inc   Report issue

For profit Phase 1 Phase 2
Founded: Seattle WA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03820414
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Curevo Inc | Curevo Vaccine

Active Ingredients

Drugs in Phase 2 Trials (2)

crv-101 (1 trial)

varicella zoster virus glycoprotein e antigen (Shingrix) (1 trial)

Drugs in Phase 1 Trials (1)

crv 101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Herpes Zoster (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3